tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Progress and Strategic Focus Drive Buy Rating for Mersana Therapeutics
PremiumRatingsPromising Progress and Strategic Focus Drive Buy Rating for Mersana Therapeutics
16d ago
Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)
Premium
The Fly
Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)
16d ago
MRSN Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
MRSN Upcoming Earnings Report: What to Expect?
18d ago
Mersana Therapeutics’ XMT-1660 Study: A Potential Game-Changer in Cancer Treatment
PremiumCompany AnnouncementsMersana Therapeutics’ XMT-1660 Study: A Potential Game-Changer in Cancer Treatment
1M ago
Mersana Therapeutics Advances HER2-Targeted Cancer Therapy with XMT-2056 Study
Premium
Company Announcements
Mersana Therapeutics Advances HER2-Targeted Cancer Therapy with XMT-2056 Study
2M ago
Mersana Therapeutics Settles Debt with Oxford Finance
Premium
Company Announcements
Mersana Therapeutics Settles Debt with Oxford Finance
2M ago
Promising Clinical Trial Data and Upcoming Presentations Bolster Buy Rating for Mersana Therapeutics
PremiumRatingsPromising Clinical Trial Data and Upcoming Presentations Bolster Buy Rating for Mersana Therapeutics
3M ago
Promising Efficacy and Strategic Positioning of Mersana Therapeutics’ Emi-Le Drive Buy Rating
Premium
Ratings
Promising Efficacy and Strategic Positioning of Mersana Therapeutics’ Emi-Le Drive Buy Rating
3M ago
Mersana Therapeutics price target raised to $10 from $9 at Truist
Premium
The Fly
Mersana Therapeutics price target raised to $10 from $9 at Truist
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100